关于控股股东、实际控制人之一致行动人减持股份变动触及 1%暨减持计划实施完毕的公告 公司控股股东广东金欧健康科技有限公司及其一致行动人广东侨银房地产 开发有限公司、汕头市银康企业管理咨询合伙企业（有限合伙）保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 11 月 11 日 在巨潮资讯网（www.cninfo.com.cn）披露了《关于控股股东、实际控制人之一 致行动人股份减持计划的预披露公告》（公告编号：2025-055），股东汕头市银 康企业管理咨询合伙企业（有限合伙）（以下简称"银康管理"）计划自该公告 披露之日起十五个交易日后的三个月内以集中竞价交易方式合计减持公司股份 不超过 1,061,520 股，即减持比例不超过公司总股本的 0.66%。 证券代码：301111 证券简称：粤万年青 公告编号：2025-062 广东万年青制药股份有限公司 近日，公司收到银康管理出具的《告知函》,获悉银康管理于 2025 年 12 月 3 日至 20 ...

三大指数早盘集体上涨，截至午盘，上证指数涨0.08%，深成指涨0.39%，创业板指涨0.47%，北证50涨涨0.47%。沪深京 三市半日成交额9996亿元，较上日缩量406亿元。全市场超3500只个股上涨。 板块题材方面，算力硬件、有色金属、可控核聚变、福建板块涨幅居前；银行、医药板块跌幅居前。 盘面上，算力硬件表现强势，CPO、铜缆高速连接方向领涨，长光华芯20CM涨停股价创新高，宝胜股份、致尚科技、青 山纸业等涨停。有色金属持续走强，闽发铝业、精艺股份涨停，晓程科技涨超10%。可控核聚变板块走高，永鼎股份涨停，国 机重装此前涨停晋级3连板。福建本地股表现活跃，东百集团等十余股涨停。银行板块表现低迷，重庆银行跌超3%。医药概念 走低，粤万年青跌超5%。 ...

具体来看，今日上榜的营业部中，共有3家机构专用席位现身，即买一、买二、买三、卖二、卖三，合 计买入金额5823.44万元，卖出金额5254.40万元，合计净买入569.05万元。 资金流向方面，今日该股主力资金净流入4025.61万元，其中，特大单净流入1031.71万元，大单资金净 流入2993.90万元。近5日主力资金净流入3418.01万元。（数据宝） 粤万年青12月3日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 机构专用 | 2489.37 | 2168.24 | | 买二 | 机构专用 | 1668.88 | 2142.50 | | 买三 | 机构专用 | 1665.19 | 943.65 | | 买四 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | 1373.51 | 680.69 | | 买五 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | 1224.21 | 978.25 | | 卖一 | 广发证券股份有限公司汕头迎宾路证券营业部 | ...

Group 1 - The core viewpoint of the articles highlights the active performance of flu-related stocks in the A-share market, driven by a rising trend in acute respiratory infectious diseases in China, particularly influenza [1][2] - The National Influenza Center reported that 17 provinces in China have reached high flu levels, with expectations of peak activity in mid-December [1] - The dominant circulating strain is the H3N2 subtype, accounting for over 95% of cases, with some H1N1 and B strains also present [1] Group 2 - Recent data indicates a significant increase in orders for antiviral medications, with orders for flu-specific drugs rising nearly ninefold compared to October, particularly for Maviroc and Oseltamivir [2] - Various pharmaceutical companies have shown notable stock price increases, with Guangdong Wannianqing rising over 11% and other companies like Yisheng Pharmaceutical and Jindike also experiencing substantial gains [3] - The overall supply of flu-related medications is reported to be sufficient, with recommendations for consumers to avoid panic buying [2]

Group 1 - The flu-related concept stocks experienced significant fluctuations, with Yingke Group hitting the daily limit up [1] - Haiwang Bio and Yisheng Pharmaceutical also reached the daily limit up, indicating strong market interest [1] - Yue Wannianqing saw an increase of over 10%, while companies like Guangji Pharmaceutical, Panlong Pharmaceutical, and Jindike also experienced gains [1]

New Stock Listings - Jingchuang Electric (920035) listed at an issuance price of 12.10 on December 2, 2025[1] - Tianpu Co., Ltd. (605255) is in the offer period from November 20 to December 19, 2025[1] Market Alerts - ST Suwu (600200) enters the delisting arrangement period starting December 9, 2025[1] - Jianglong Shipbuilding (300589) reported severe abnormal fluctuations[1] Recent Announcements - Multiple companies including Beida Pharmaceutical (000788) and ST Green Health (002868) have recent announcements regarding their stock activities[1] - A total of 30 companies have been flagged for abnormal trading activities in the last week[2]

Core Insights - The recent monitoring indicates that China has entered a high incidence season for respiratory infectious diseases, with an overall upward trend in the epidemic, primarily driven by influenza viruses [1][2] - The stock market has seen a significant rise in the influenza concept sector, reaching a five-year high on November 14, 2023, and showing continued interest in related stocks [4][5] Group 1: Influenza Monitoring and Trends - The percentage of influenza-like cases has been continuously rising, with a national positive rate of 40.9% for influenza [2] - A total of 1,234 influenza-like case outbreaks were reported, an increase of 279 from the previous week, with schools seeing a rise in clustered outbreaks [2] - The demand for influenza testing kits has surged, with sales doubling in the last week, particularly in Beijing, Tianjin, and Hebei [2][3] Group 2: Stock Market Performance - The influenza concept index rose by 2.74% on October 31, followed by a cumulative increase of 5.37% in the first ten trading days of November, peaking at 1,659.53 points on November 14 [4] - As of December 1, the index closed at 1,574.18 points after a brief adjustment period [4] Group 3: Individual Stock Performance - Companies such as Haiwang Biological, Yue Wannianqing, and Tailong Pharmaceutical have seen significant stock price increases, with Haiwang Biological's stock rising over 52% since November 24 [5] - Yue Wannianqing's stock reached a peak of 26.47 yuan per share, marking a cumulative increase of 57.84% [5] - Tailong Pharmaceutical's stock saw a cumulative increase of 17.55%, reaching a historical high of 8.84 yuan per share [5] Group 4: Market Demand and Supply Chain Response - JD Health has formed an IVD brand alliance to meet the rising demand for testing kits and ensure stable product supply during peak periods [3] - The demand for antiviral medications has surged, with sales of Oseltamivir increasing by 4.5 times and Mavrirol increasing by 5 times in the week of November 17 to November 23 [3][6] - Analysts predict that the demand for cold medications in the fourth quarter will exceed market expectations, supported by the introduction of multi-detection products and convenient diagnostic tools [6]

从资金流向上来看，当日中药板块主力资金净流出3.29亿元，游资资金净流入2.1亿元，散户资金净流入 1.19亿元。中药板块个股资金流向见下表： 证券之星消息，12月1日中药板块较上一交易日上涨0.82%，粤万年青领涨。当日上证指数报收于 3914.01，上涨0.65%。深证成指报收于13146.72，上涨1.25%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301111 | 粤万年青 | 25.11 | 9.94% | 33.41万 | | 8.15亿 | | 600222 | 太龙药业 | 8.58 | 6.72% | 89.74万 | | 7.66亿 | | 600750 | 江中药业 | 22.67 | 4.37% | 24.14万 | | 5.46亿 | | 000790 | 华神科技 | 4.39 | 3.78% | 37.98万 | | 1.66亿 | | 600993 | 马应龙 | 28.41 | 3.53% | 6.60万 | | ...

Group 1 - The flu-related concept has become active again, with Haiwang Bio hitting the daily limit up [2] - Yue Wannianqing has increased by over 12% [2] - Other companies such as Guangji Pharmaceutical, Hendi Pharmaceutical, Te Yi Pharmaceutical, Jinshi Yiyao, and Xinhua Pharmaceutical have also seen gains [2]

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 2.67%, underperforming the Wind All A index (2.9%) but outperforming the CSI 300 index (1.64%). The raw material drug sector experienced a decline of 4.27%, while chemical preparations and pharmaceutical circulation products increased by 4.18% and 3.71%, respectively [3][8] - Recent policies in Shanghai and Beijing aim to support the high-quality development of the medical device industry, indicating a shift towards innovation and global competitiveness in this sector. The report suggests monitoring the transformation progress of leading companies in the medical device field [3][12] - Flu activity is on the rise, with the percentage of flu-like cases reported by sentinel hospitals in southern provinces reaching 7.8%, up from 6.8% the previous week, and higher than the same period in 2022 and 2024 [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector increased by 2.67% from November 24 to November 28, 2025, with raw material drugs declining by 4.27% and chemical preparations increasing by 4.18% [8][9] - Individual stock performances included significant gains for Haiwang Biological (38.2%), Yue Wannianqing (36.2%), and Guangji Pharmaceutical (31.7%), while *ST Changyao (-15.3%), Huitai Medical (-9.6%), and Kangwei Century (-8.8%) saw notable declines [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu-like illness percentages in both southern (7.8%) and northern (8.6%) provinces, indicating a significant rise in flu activity compared to previous years [11][12] Industry News - Significant approvals were noted, including the NMPA's approval of Xinmeiyue® for treating moderate to severe plaque psoriasis and the FDA's accelerated approval of Sibeprenlimab for IgAN treatment [12][14] Company Announcements - Notable announcements include the FDA approval of a generic injectable drug by Jianyou Co. and the successful completion of a Phase III trial for JS001sc, a subcutaneous PD-1 monoclonal antibody for non-small cell lung cancer [15][16]